P397 -

Research on the effectiveness of the drug for inducing remission in Inflammatory Bowel Disease.

Analysis of distinct blood protein profiles in patients with ileal and colonic ulcers.

: It was formally approved by the energy regulator, Ofgem , in October 2020 and implemented on October 12, 2020 . Research on the effectiveness of the drug for

: "Assessing the costs and benefits of adjusting Parties' Imbalance Prices for the effects of the Capacity Market".

is a designation used in various technical and academic contexts, most significantly in energy regulation and medical research . 1. Energy Regulation (Elexon P397) : "Assessing the costs and benefits of adjusting

A case study on caused by specific variants in the CHRNE gene.

A report expanding the phenotypic spectrum of , focusing on neurodevelopmental traits like ADHD and autism. Energy Regulation (Elexon P397) A case study on

: The proposal aimed to adjust energy imbalance prices to better account for the impacts of the Capacity Market , ensuring that prices reflect the true cost of balancing the system.